Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
104 results about "Nicotinic Receptors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Compositions for Reducing Nicotine Withdrawal Symptoms and/or Tobacco Usage
InactiveUS20100040679A1Reducing nicotine withdrawal symptomRelieve symptomsBiocideNervous disorderDrug withdrawal symptomsMetabolite
Compositions useful for treating an individual with nicotine dependence comprising a combination of an α3β4 nicotinic receptor antagonist and a nicotine metabolite are disclosed. More particularly, compositions comprising cotinine or a pharmaceutically acceptable salt thereof are disclosed. Methods of alleviating nicotine withdrawal symptoms and / or tobacco usage by administration of these compositions are also disclosed.
Owner:SMITHKLINE BECKMAN CORP
1,3,5-trisubstituted triazole derivative
ActiveUS20100240707A1Good curative effectBiocideNervous disorderAllosteric modulatorTriazole derivatives
The present invention relates to 2-[3-(2,2-Difluoro-benzo[1,3]dioxol-5-ylamino)-5-(2,6-dimethyl-pyridin-4-yl)-[1,2,4]triazol-1-yl]-N-ethyl-acetamide and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy.The invention particularly relates to a potent positive allosteric modulator of nicotinic acetylcholine receptors which have the capability of increasing the efficacy of nicotinic receptor agonists.
Owner:JANSSEN PHARMA NV
Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof
The present application describes selective ligands of formula (I)for neuronal nicotinic receptors (NNRs), more specifically for the α4β2 NNR subtype, compositions thereof, and methods of using the same, wherein X, R1, X, R2, R3, L1, m, n, p, and q are defined in the specification.
Owner:ABBVIE INC
Positive modulators of nicotinic receptors
InactiveUS6861443B2Good curative effectRestore normal interneuronal communicationBiocideNervous disorderNicotinic Receptor AgonistReceptor for activated C kinase 1
The present invention relates to pharmaceutical compositions comprising a positive modulator of a nicotinic receptor agonist, said positive modulator having the capability to increase the efficacy of the said nicotinic receptor agonist.
Owner:ASTRAZENECA AB
Nicotinic receptor agonists for the treatment of inflammatory diseases
InactiveUS20050130990A1Minimize impactMinor side effectsBiocideOrganic chemistrySide effectAntiinflammatory drug
Owner:UNIV LAVAL
Positive modulators of nicotinic receptor agonists
Compounds of Formula Iwherein R1, R2, R3, R4, R5, W and X as defined in the specification, enantiomers thereof, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission. Compounds of the invention enhance the efficacy of agonists at nicotinic receptors.
Owner:ASTRAZENECA AB
Methods and compositions for reduction of side effects of therapeutic treatments
The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.
Owner:THE PARKINSONS INST
Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
A method of inhibiting excitotoxicity by indirectly activating α4β2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of α7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate α4β2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.
Owner:NEUROPROTECTION FOR LIFE CORP
Certain heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
Owner:DANPET
Trisubstituted pyrazoles as acetylcholine receptor modulators
The present invention relates to 1-alkyl-3-aniline-5-aryl-pyrazole derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I).The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulator having the capability to increase the efficacy of nicotinic receptor agonists.
Owner:JANSSEN PHARMA NV
Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
InactiveUS20030199496A1Relief the painIncreased dopamineBiocidePeptide/protein ingredientsAntiepileptic drugAmphetamine use
A pharmaceutical composition comprising an .alpha.3.beta.4 nicotinic receptor antagonist effective to diminish the brain-derived feeling of pleasure due to increased dopamine in the pleasure-reward center of the brain typically associated with administration of an opioid agonist analgesic, a muscle relaxant, an anti-seizure medication, an anxiolytic drug, an amphetamine, a central nervous system stimulant, a tetrahydrocannabinol or that associated with an otherwise pleasurable or self-reinforcing behavior.
Owner:SIMON DAVID LEW
Nicotinic receptor agonists and analogues and derivatives thereof for the treatment of inflammatory diseases
InactiveUS20070249622A1Minimize impactMinor side effectsOrganic active ingredientsOrganic chemistrySide effectAntiinflammatory drug
Owner:UNIV LAVAL
Trisubstituted 1,2,4-triazoles
Owner:JANSSEN PHARMA NV
Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines
ActiveUS20120172354A1Good curative effectBiocideNervous disorderAllosteric modulatorNicotinic Receptor Agonist
The present invention relates to N-phenyl-1-(4-pyridinyl)-1H-pyrazol-3-amine derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to formula (I)Wherein R1, R2, R3, R4, R5, R6 have the meaning defined in the claims.The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulator having the capability to increase the efficacy of nicotinic receptor agonists.
Owner:JANSSEN PHARMA NV
Trisubstituted 1,2,4 triazoles
The present invention relates to substituted 1-(alkyl)-3-aniline-5-aryl triazole derivatives and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I).The invention particularly relates to potent positive allosteric modulators of nicotinic acetylcholine receptors which have the capability of increasing the efficacy of nicotinic receptor agonists.
Owner:JANSSEN PHARMA NV
Neuronal nicotinic receptor ligands and their use
InactiveUS20070184490A1Reduce incidenceWell-tolerated side effectCompound screeningBiocideTolerabilitySide effect
The invention relates to neuronal nicotinic receptor ligands, methods of identifying such ligands for neuronal nicotinic receptor modulation, particularly such ligands demonstrating beneficial side effect tolerability, and methods of using such neuronal nicotinic receptor ligands to provide pharmaceutical compositions and products.
Owner:ABBOTT LAB INC
Positive modulators of nicotinic receptor agonists
InactiveUS20050245595A1Enhance efficacy of agonistRestore normal interneuronal communicationBiocideNervous disorderEnantiomerNicotinic Receptor Agonist
Owner:ASTRAZENECA AB
Pharmaceutical composition for the prevention and treatment of addiction in a mammal
InactiveUS20050043407A1Relieve symptomsReduce usageBiocideOrganic active ingredientsSubstance abuserCocaine dependence
Pharmaceutical compositions are disclosed for the treatment of alcohol or cocaine dependence or addiction, alcohol dependence or addiction, reduction of alcohol withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse or other behavioral dependencies. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and an alpha2delta ligand and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.
Owner:PFIZER INC
Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
The disclosure generally relates to compounds of the following formula, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
Owner:BRISTOL MYERS SQUIBB CO
Trisubstituted 1,2,4 triazoles
The present invention relates to 1-aryl-3-aniline-5-alkyl-1,2,4-triazole derivatives and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I).The invention particularly relates to potent positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulator having the capability to increase the efficacy of nicotinic receptor agonists.
Owner:JANSSEN PHARMA NV
Selective substituted pyridine ligands for neuronal nicotinic receptors
The present application describes selective ligands of formula (I)for neuronal nicotinic receptors (NNRs), more specifically for the α4β2 NNR subtype, compositions thereof, and methods of using the same, wherein X, R1, X, R2, R3, L1, m, n, p, and q are defined in the specification.
Owner:ABBVIE INC
Nicotinic receptor non-competitive antagonists
The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.
Owner:TARGACEPT INC
Genomic DNA fragments containing regulatory and coding sequence for the beta2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments
Several genes encoding subunits of the neuronal nicotinic acetylcholine receptors have been cloned and regulatory elements involved in the transcription of the ∝:2 and ∝:7-subunit genes have been described. Yet, the detailed mechanisms governing the neuron-specific transcription and the spatio-temporal expression pattern of these genes remain largely uninvestigated. The β2-subunit is the most widely expressed neuronal nicotinic receptors subunit in the nervous system. We have studied the structural and regulatory properties of the 5′ sequence of this gene. A fragment of 1163 bp of upstream sequence is sufficient to drive the cell-specific transcription of a reporter gene in both transient transfection assays and in transgenic mice. Deletion analysis and site-directed mutagenesis of this promoter reveal two negative and one positive element. The positively acting sequence includes one functional E-box. One of the repressor elements is located in the transcribed region and is the NRSE / RE1 sequence already described in promoters of neuronal genes.
Owner:INST PASTEUR
Alpha 7 nicotinic receptor selective ligands
The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Treating Inflammatory Disorders With Antibodies to the Alpha-7 Nicotinic Receptors
InactiveUS20090324588A1Inhibit pro-inflammatory cytokine productionInhibition productionNervous disorderAntipyreticAntigenAntigen Binding Fragment
An antibody or an antigen binding fragment thereof which binds to mammalian α7 subunit of a nicotinic acetylcholine receptor or its functional variant and which is an agonist of said receptor or variant. Pharmaceutical compositions comprising same. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject an antibody or an antigen-binding fragment as described herein.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
InactiveUS7091357B2Potent and selective antagonistic activityBiocideOrganic chemistryDiseaseStimulant
Owner:UNIV OF KENTUCKY RES FOUND
Blocking of cue-induced drug reinstatement
InactiveUS20150051192A1Improve permeabilityIncrease ratingsBiocideNervous disorderNicotinic AntagonistUse medication
A method of preventing drug use relapse by administering an effective amount of an α3β4 nicotinic antagonist to a mammal after an initial period of drug use, and preventing a relapse of drug use. A method of preventing drug use relapse due to cue inducement by administering an effective amount of an α3β4 nicotinic antagonist to a mammal after an initial period of drug use, and preventing a relapse of drug use during cue inducement. A method of preventing drug use relapse due to cue inducement by modulating the dopaminergic mesolimbic pathway by blocking α3β4 nicotinic receptors in the habenulo-interpeduncular pathway and the basolateral amygdala of a mammal after an initial period of drug use, and preventing a relapse of drug use during cue inducement. A method of preventing drug use relapse by preventing a relapse of drug use during cue inducement.
Owner:ALBANY MEDICAL COLLEGE
Organic compounds
ActiveUS20140205596A1Increase awarenessLess lipophilicBiocideHeavy metal active ingredientsDiseaseMedicine
The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.
Owner:INTRA CELLULAR THERAPIES INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com